S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
183 Pounds of Copper for Just ONE EV (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
183 Pounds of Copper for Just ONE EV (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Walmart employee who survived mass shooting at store in Virginia has filed a $50 million lawsuit against the company
Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
183 Pounds of Copper for Just ONE EV (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
183 Pounds of Copper for Just ONE EV (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Walmart employee who survived mass shooting at store in Virginia has filed a $50 million lawsuit against the company
Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
183 Pounds of Copper for Just ONE EV (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
183 Pounds of Copper for Just ONE EV (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Walmart employee who survived mass shooting at store in Virginia has filed a $50 million lawsuit against the company
Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
183 Pounds of Copper for Just ONE EV (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
183 Pounds of Copper for Just ONE EV (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Walmart employee who survived mass shooting at store in Virginia has filed a $50 million lawsuit against the company
Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
NASDAQ:ASND

Ascendis Pharma A/S - ASND Stock Forecast, Price & News

$118.42
-1.08 (-0.90%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$116.62
$120.74
50-Day Range
$98.65
$131.97
52-Week Range
$61.58
$147.90
Volume
147,006 shs
Average Volume
521,037 shs
Market Capitalization
$6.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$159.55

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
34.7% Upside
$159.55 Price Target
Short Interest
Bearish
17.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Ascendis Pharma A/S in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($9.10) to ($10.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

563rd out of 1,038 stocks

Pharmaceutical Preparations Industry

270th out of 510 stocks

ASND stock logo

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

What 9 Analyst Ratings Have To Say About Ascendis Pharma
6 Analysts Have This to Say About Ascendis Pharma
15 Most Valuable Danish Companies in the World
Ascendis Pharma: TransCon CNP Data Coming Q4
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Company Calendar

Last Earnings
11/09/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
639
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$159.55
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+34.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-453,810,000.00
Net Margins
-1,473.30%
Pretax Margin
-1,475.40%

Debt

Sales & Book Value

Annual Sales
$9.20 million
Book Value
$7.98 per share

Miscellaneous

Free Float
34,216,000
Market Cap
$6.75 billion
Optionable
Optionable
Beta
0.55

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 62)
    Pres, CEO, Member of Exec. Board & Exec. Director
  • Mr. Michael Wolff Jensen L.L.M. (Age 51)
    Sr. VP, Chief Legal Officer & Member of the Exec. Board
  • Dr. Birgitte Volck M.D. (Age 60)
    Ph.D., Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs
    Comp: $23.95k
  • Mr. Scott T. Smith (Age 48)
    CFO, Sr. VP & Member of Exec. Board
  • Ms. Lotte Sonderbjerg (Age 61)
    Chief Admin. Officer, Sr. VP & Member of the Exec. Board
  • Mr. Peter Rasmussen (Age 53)
    VP of Fin. & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Sr. Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 61)
    Sr. VP of Product Supply & Quality
  • Dr. Kennett Sprogoe (Age 43)
    Sr. VP and Head of Innovation & Research
  • Dr. Jens Sigurd Okkels Ph.D. (Age 61)
    Sr. VP of Product Devel.













ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price forecast for 2023?

12 brokerages have issued 1 year target prices for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $130.00 to $182.00. On average, they anticipate the company's stock price to reach $159.55 in the next year. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2022?

Ascendis Pharma A/S's stock was trading at $134.53 at the beginning of the year. Since then, ASND shares have decreased by 12.0% and is now trading at $118.42.
View the best growth stocks for 2022 here
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $1.13. The biotechnology company earned $1.31 million during the quarter, compared to analyst estimates of $1.60 million. Ascendis Pharma A/S had a negative net margin of 1,473.30% and a negative trailing twelve-month return on equity of 71.44%. During the same period last year, the firm posted ($2.70) EPS.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (12.54%), Price T Rowe Associates Inc. MD (6.79%), Massachusetts Financial Services Co. MA (2.08%), Spyglass Capital Management LLC (1.67%), Putnam Investments LLC (1.38%) and Alliancebernstein L.P. (1.12%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $118.42.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $6.75 billion and generates $9.20 million in revenue each year. The biotechnology company earns $-453,810,000.00 in net income (profit) each year or ($9.21) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

The company employs 639 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 11/30/2022 by MarketBeat.com Staff